肝内胆管癌
医学
放射治疗
背景(考古学)
疾病
肿瘤科
罕见病
内科学
生物
古生物学
作者
Eugene J. Koay,Milind Javle,Madeline Belknap,Shrey Derasari,M. Roach,Ethan B. Ludmir
出处
期刊:The cancer journal
[Ovid Technologies (Wolters Kluwer)]
日期:2023-09-01
卷期号:29 (5): 272-278
标识
DOI:10.1097/ppo.0000000000000685
摘要
Abstract Intrahepatic cholangiocarcinoma is a rare disease, yet with rising incidence globally. Most patients are not eligible for potentially curative surgical resection, and many patients with unresectable disease die within 12 months of diagnosis, primarily due to liver failure from the primary tumor. Recent prospective and retrospective studies indicate that local control of the primary tumor can be achieved with hypofractionated radiotherapy in patients with unresectable disease, translating into prolonged survival of these patients. During the time that these encouraging reports for radiotherapy have been published, numerous concurrent studies have also shown that intrahepatic cholangiocarcinoma is a molecularly diverse disease with multiple targetable genetic alterations and a complex tumor microenvironment. These biological insights have translated into new drug approvals for subsets of patients. We review the current knowledge about the biology and targeted treatment of intrahepatic cholangiocarcinoma and describe these developments in the context of modern radiotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI